Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Convertible Debt (2019 - 2024)

Bioadaptives' Convertible Debt history spans 6 years, with the latest figure at $461000.0 for Q4 2024.

  • Quarterly results put Convertible Debt at $461000.0 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $461000.0 (changed N/A YoY), and the annual figure for FY2024 was $461000.0, changed.
  • Convertible Debt for Q4 2024 was $461000.0 at Bioadaptives, up from $311000.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $479284.0 in Q2 2021 to a low of $311000.0 in Q2 2024.
  • The 5-year median for Convertible Debt is $388967.0 (2020), against an average of $383833.9.
  • The sharpest move saw Convertible Debt surged 112.63% in 2020, then decreased 28.24% in 2023.
  • Year by year, Convertible Debt stood at $405236.0 in 2020, then decreased by 0.52% to $403117.0 in 2021, then fell by 5.29% to $381793.0 in 2022, then fell by 14.7% to $325671.0 in 2023, then skyrocketed by 41.55% to $461000.0 in 2024.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $461000.0, $311000.0, and $311000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.